60 studies found for:    gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3
Show Display Options
Rank Status Study
21 Recruiting Re-expression of ER in Triple Negative Breast Cancers
Conditions: Breast Cancer;   Breast Tumors;   Breast Neoplasms
Intervention: Drug: Decitabine, LHB589, Tamoxifen
22 Recruiting LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: Erismodegib;   Drug: Placebo
23 Recruiting Cyclophosphamide With or Without Veliparib in Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: veliparib;   Drug: cyclophosphamide;   Other: placebo;   Other: laboratory biomarker analysis
24 Recruiting Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Intervention: Drug: Orteronel
25 Recruiting Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
26 Unknown  Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery
Condition: Breast Cancer
Interventions: Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride
27 Recruiting 18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Hypopharyngeal Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Laryngeal Cancer;   Recurrent Lip and Oral Cavity Cancer;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Nasopharyngeal Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Oropharyngeal Cancer;   Recurrent Pancreatic Cancer;   Recurrent Paranasal Sinus and Nasal Cavity Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Colon Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: fludeoxyglucose F 18;   Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
28 Recruiting A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Conditions: Luminal A Breast Cancer;   Luminal B Breast Cancer;   CPS-EG Score;   Postneoadjuvant Treatment With CDK 4/6 Inhibitor;   Hormonreceptor Positive
Interventions: Drug: Palbociclib PD-0332991;   Behavioral: Patient reported outcomes;   Drug: Placebo
29 Recruiting A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
Condition: Early Breast Cancer
Interventions: Drug: LEE011;   Drug: Letrozole
30 Recruiting Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Condition: HER2 Low to Intermediate Breast Cancer
Interventions: Biological: NeuVax™ vaccine;   Biological: Leukine® (sargramostim, GM-CSF) and water for injection
31 Recruiting Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
32 Not yet recruiting Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: MK-3475
33 Recruiting Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Temsirolimus plus Neratinib
34 Not yet recruiting Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
Condition: Breast Neoplasms
Interventions: Drug: Letrozole;   Drug: Afatinib
35 Recruiting Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Taxotere;   Drug: Adriamycin/Cytoxan;   Drug: docetaxol;   Drug: doxorubicin
36 Recruiting Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Trastuzumab Emtansine;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Abraxane;   Drug: Paclitaxel
37 Recruiting A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Paclitaxel
38 Recruiting Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
39 Recruiting ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Conditions: Breast Cancer;   Breast Disease;   Neoplasms;   Neoplasms by Site
Intervention: Drug: cyclophosphamide, Adriamycin, Docetaxel, Trastuzumab, Zolendronic acid
40 Recruiting A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Metformin;   Drug: Placebo

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years